Albireo Historical Balance Sheet

ALBO Stock  USD 44.95  0.40  0.90%   
Trend analysis of Albireo Pharma balance sheet accounts such as Receivables of 3.2 M, Accounts Payable of 6.3 M or Accumulated Other Comprehensive Income of 916.7 K provides information on Albireo Pharma's total assets, liabilities, and equity, which is the actual value of Albireo Pharma to its prevalent stockholders. By breaking down trends over time using Albireo Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down Albireo Pharma prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Albireo Pharma is a good buy for the upcoming year.
Please continue to Trending Equities.
  

About Albireo Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Albireo Pharma at a specified time, usually calculated after every quarter, six months, or one year. Albireo Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Albireo Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Albireo currently owns. An asset can also be divided into two categories, current and non-current.

Albireo Pharma Balance Sheet Chart

Albireo Pharma Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Albireo Pharma uses and utilizes its capital. It also shows what exactly a company owns and owes.
Albireo Pharma Cash and Equivalents is quite stable at the moment as compared to the past year. The company's current value of Cash and Equivalents is estimated at 240.92 Million. Shareholders Equity is expected to rise to about 170.5 M this year, although the value of Accumulated Other Comprehensive Income will most likely fall to about 916.7 K.

Total Assets

Total assets refers to the total amount of Albireo Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Albireo Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; [Investments]; Goodwill and Intangible Assets; Property Plant and Equipment Net; Tax Assets and Trade and Non Trade Receivables.

Current Assets

Current assets of Albireo Pharma include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Albireo Pharma. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on Albireo Pharma balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Albireo Pharma books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; [DeferredRev]; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.
Most accounts from Albireo Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Albireo Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please continue to Trending Equities.Albireo Pharma Cash and Equivalents is quite stable at the moment as compared to the past year. The company's current value of Cash and Equivalents is estimated at 240.92 Million. Shareholders Equity is expected to rise to about 170.5 M this year, although the value of Accumulated Other Comprehensive Income will most likely fall to about 916.7 K.
 2022 2023 (projected)
Receivables2.94 M3.18 M
Inventories174.6 K173.58 K

Albireo Pharma balance sheet Correlations

-0.44-0.55-0.56-0.56-0.68-0.54-0.51-0.69-0.52-0.53-0.281.0-0.59-0.68-0.67-0.690.01-0.560.180.29
-0.440.960.940.940.850.940.740.80.820.940.59-0.440.940.840.930.93-0.220.95-0.43-0.46
-0.550.960.970.960.910.960.740.820.820.950.51-0.550.980.920.960.94-0.030.88-0.27-0.32
-0.560.940.971.00.91.00.740.820.810.990.53-0.560.990.940.980.95-0.130.89-0.36-0.41
-0.560.940.961.00.881.00.750.790.780.990.51-0.560.990.930.980.95-0.120.89-0.35-0.4
-0.680.850.910.90.880.870.610.970.950.890.62-0.680.910.950.880.9-0.210.79-0.4-0.46
-0.540.940.961.01.00.870.750.790.780.990.52-0.540.980.910.980.95-0.140.9-0.36-0.41
-0.510.740.740.740.750.610.750.560.520.740.31-0.510.720.630.750.750.010.75-0.22-0.29
-0.690.80.820.820.790.970.790.560.980.820.67-0.690.810.850.80.84-0.310.75-0.44-0.51
-0.520.820.820.810.780.950.780.520.980.820.7-0.520.790.810.760.8-0.350.73-0.47-0.52
-0.530.940.950.990.990.890.990.740.820.820.56-0.530.970.910.960.94-0.180.88-0.39-0.43
-0.280.590.510.530.510.620.520.310.670.70.56-0.280.490.510.50.64-0.740.63-0.65-0.66
1.0-0.44-0.55-0.56-0.56-0.68-0.54-0.51-0.69-0.52-0.53-0.28-0.59-0.68-0.67-0.690.01-0.560.180.29
-0.590.940.980.990.990.910.980.720.810.790.970.49-0.590.960.990.96-0.070.89-0.32-0.38
-0.680.840.920.940.930.950.910.630.850.810.910.51-0.680.960.930.93-0.090.8-0.33-0.39
-0.670.930.960.980.980.880.980.750.80.760.960.5-0.670.990.930.98-0.10.92-0.34-0.4
-0.690.930.940.950.950.90.950.750.840.80.940.64-0.690.960.930.98-0.230.94-0.42-0.49
0.01-0.22-0.03-0.13-0.12-0.21-0.140.01-0.31-0.35-0.18-0.740.01-0.07-0.09-0.1-0.23-0.350.860.83
-0.560.950.880.890.890.790.90.750.750.730.880.63-0.560.890.80.920.94-0.35-0.52-0.56
0.18-0.43-0.27-0.36-0.35-0.4-0.36-0.22-0.44-0.47-0.39-0.650.18-0.32-0.33-0.34-0.420.86-0.520.98
0.29-0.46-0.32-0.41-0.4-0.46-0.41-0.29-0.51-0.52-0.43-0.660.29-0.38-0.39-0.4-0.490.83-0.560.98
Click cells to compare fundamentals

Albireo Pharma Account Relationship Matchups

Albireo Pharma balance sheet Accounts

201820192020202120222023 (projected)
Accounts Payable4.35 M4.79 M5.28 M6.52 M5.86 M6.33 M
Accumulated Other Comprehensive Income4.29 M6.45 M(8.61 M)1.1 M994.5 K916.74 K
Total Assets185.47 M165.07 M285.61 M302.05 M271.85 M293.31 M
Current Assets167.65 M141.8 M261.87 M268.93 M242.04 M261.15 M
Assets Non Current17.82 M23.27 M23.74 M33.12 M38.09 M41.1 M
Cash and Equivalents163.88 M131.84 M251.27 M248.11 M223.3 M240.92 M
Cash and Equivalents USD163.88 M131.84 M251.27 M248.11 M285.32 M307.85 M
Shareholders Equity122.64 M93.16 M181.23 M175.61 M158.05 M170.52 M
Shareholders Equity USD122.64 M93.16 M181.23 M175.61 M201.95 M217.89 M
Total Liabilities62.83 M71.91 M104.38 M126.44 M113.8 M122.78 M
Current Liabilities12.82 M18.92 M25.28 M45.35 M40.81 M44.03 M
Liabilities Non Current50 M52.98 M79.09 M81.1 M93.26 M100.62 M
Trade and Non Trade Payables4.35 M4.79 M5.28 M6.52 M7.49 M8.08 M
Property Plant and Equipment Net187 K597 K478 K668 K601.2 K602.74 K
Accumulated Retained Earnings Deficit(96.47 M)(159.19 M)(266.82 M)(300.85 M)(270.76 M)(277.89 M)

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-0.78CVSCVS Health Corp Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
915.3 M
Quarterly Revenue Growth
1.683
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.